Rhythm Pharmaceuticals (RYTM) Tops Q4 EPS by 2c

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q4 EPS of ($0.72), $0.02 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $41.83 million versus the consensus estimate of $36.04 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Morgan Stanley Upgrades Galp Energia SGPS SA (GALP:LI) (GLPEF) to Overweight
• JPMorgan Starts Kanzhun Ltd (2076:HK) at Overweight